Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for hematologic malignancies and coronary artery disease. However, its role in peripheral artery disease (PAD) and the specific impact of DNA damage repair (DDR) gene mutations, such as TP53, have remained unclear. This study, utilizing data from over 50,000 individuals and mechanistic mouse models, demonstrates that CHIP—particularly when involving DDR genes—significantly increases the risk of incident PAD. Unlike other common CHIP mutations that drive atherosclerosis through inflammation, TP53 mutations promote disease by accelerating macrophage proliferation directly within arterial plaques.
Introduction
As the human body ages, hematopoietic stem cells accumulate somatic mutations. When these mutated cells gain a competitive advantage and expand into a large "clone" of blood cells, the condition is known as Clonal Hematopoiesis of Indeterminate Potential (CHIP). While previous research has established links between CHIP and both blood cancers and coronary artery disease, its influence on the broader vascular system, specifically peripheral artery disease (PAD), has been less understood.
Furthermore, most research has focused on epigenetic regulators like DNMT3A and TET2. This study shifts the focus toward DNA Damage Repair (DDR) genes, such as TP53 and PPM1D. These mutations are of particular clinical interest because they are frequently selected for during cytotoxic chemotherapy, potentially predisposing cancer survivors to accelerated cardiovascular disease.
Methodology
The researchers employed a cross-disciplinary approach to investigate the link between CHIP and PAD:
- Human Genomic Analysis: The team analyzed Whole Exome Sequencing (WES) data from 50,122 individuals across the UK Biobank (UKB) and the Mass General Brigham Biobank (MGBB). They identified 2,851 CHIP carriers and used Cox proportional hazards models to assess the risk of incident PAD and atherosclerosis across various arterial beds.
- Mechanistic Mouse Models: To establish causality, the researchers performed competitive bone marrow transplantations (BMT) in atherosclerosis-prone Ldlr-/- mice. These "chimeric" mice were engineered to have 20% Trp53-deficient hematopoietic cells, mimicking the human CHIP scenario. The mice were then monitored for plaque development and macrophage accumulation.
Key Findings
Broad Atherosclerotic Risk
The study confirmed that CHIP is a systemic driver of atherosclerosis. Beyond coronary arteries, CHIP was associated with increased risks in the mesenteric arteries and the aorta (including aneurysms). CHIP carriers overall faced a 1.7-fold increased risk for incident PAD (P=2.2×10⁻⁵).
The Potency of DDR Mutations
Mutations in DDR genes carried a significantly higher risk profile. Individuals with DDR CHIP had a 2.0-fold increased risk of PAD. Specifically, TP53 mutations were associated with a nearly five-fold increase in PAD risk (HR 4.98), highlighting the aggressive nature of this specific clonal expansion.
A Unique Pathological Mechanism
A critical discovery of this research is the mechanistic divergence between TP53 and other CHIP mutations. While mutations in genes like TET2 typically drive atherosclerosis through the "inflammasome" (increasing pro-inflammatory cytokines like IL-1β and IL-6), TP53-deficient cells did not show increased expression of these markers in the atherosclerotic aortic wall.
Instead, TP53-deficient macrophages demonstrated a selective proliferative advantage within the arterial wall. In the mouse models, while mutant cells comprised approximately 48% of circulating monocytes, they accounted for ~76% of the macrophages within the plaques. This suggests that the plaque environment specifically favors the expansion of TP53-mutant cells, leading to larger, more cellular plaques.
Clinical Implications and Future Directions
These findings suggest that the cardiovascular risk associated with CHIP is not a monolith. The non-inflammatory nature of TP53-mediated atherosclerosis implies that standard anti-inflammatory therapies (such as those targeting IL-1β) may be ineffective for this specific patient subgroup.
The study also highlights a critical need for specialized cardiovascular surveillance for cancer survivors. Because chemotherapy can select for TP53 and PPM1D clones, patients treated with these agents may face a heightened risk of PAD and other atherosclerotic conditions long after their cancer treatment concludes.
Limitations
The study authors note that the human cohorts were primarily of European ancestry, necessitating further research in more diverse populations. Additionally, the reliance on Electronic Health Record (EHR) billing codes for diagnosis may introduce some misclassification. Future work will focus on identifying therapeutic strategies that can specifically target the proliferative advantage of TP53-mutant macrophages in the vasculature.
Summary updated